Nabriva
Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, has appointed Elyse Seltzer, MD, as chief medical officer. Dr. Seltzer assumes the role from Dr. William Prince, who will transition to senior vice president, clinical science.
Based in Philadelphia, Dr. Seltzer will supervise medical and regulatory aspects of clinical development and medical affairs for Nabriva and contribute to the company’s clinical development strategy. She will work closely with Dr. Steven Gelone, the recently appointed chief development officer at Nabriva, as well as the clinical operations team, to execute Nabriva’s clinical development programme, including the planned Phase 3 clinical trials of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP). Dr. Prince will be responsible for the Phase 1 and scientific programmes required to support the lefamulin development program for CABP and additional indications.
Dr. Colin Broom, Chief Executive Officer of Nabriva, commented: “We are very pleased to welcome Elyse to Nabriva. Her extensive experience in the anti-infective therapeutic area and in leading international clinical development programmes will enable us to efficiently advance our lead product, lefamulin, into late stage development for the treatment of CABP. We have established a world-class clinical development leadership team to advance our pipeline with a sense of urgency to address an area of significant medical need.”
Dr. Seltzer added: “I am thrilled to join Nabriva. I am excited to have the opportunity to advance a novel class of antibacterials, particularly given the current and evolving challenges around resistance to currently available antibiotics. I look forward to working with the highly experienced clinical team to fulfil this goal."
Dr. Seltzer has a strong track record in clinical development within the pharmaceutical industry. She joins Nabriva from GlaxoSmithKline (GSK), where she was vice president of global clinical sciences and operations. Prior to joining GSK, Dr. Seltzer was chief medical officer at Tengion, a regenerative medicine company. She has also held roles at Centocor and Vicuron, where she led the dalbavancin clinical development programme. Dr. Seltzer began her industry career in Anti-Infectives Clinical Research and Development at SmithKline Beecham (now GSK). Before joining the pharmaceutical industry, she practiced clinical Infectious Diseases medicine.
Dr. Seltzer holds an MD in Medicine from the New York University School of Medicine. She completed her Internal Medicine training at the University of Pennsylvania Medical Center and her Infectious Diseases training at Yale New Haven Hospital.